title: Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
abstract: BACKGROUND
  Both repaglinide and gliclazide are insulin secretagogues widely used in the treatment of type 2 diabetes. They stimulate insulin secretion through distinct mechanisms and may benefit patients from different aspects. The present study was to evaluate the effects of repaglinide or gliclazide on glycaemic control, insulin secretion, and lipid profiles in type 2 diabetes patients.
  
  
  METHODS
  A total of 47 newly diagnosed type 2 diabetes patients were randomized 1:1 to receive a 4-week treatment with repaglinide or gliclazide. The standard mixed meal tolerance test was performed before and after the treatment. Plasma glucose (PG), insulin concentration, and lipid profiles were measured. The area under insulin concentration curve (AUC(ins)) and the early-phase insulin secretion index (ΔI(30)/ΔG(30)) were calculated.
  
  
  RESULTS
  After the trial, fasting and postprandial PG and postprandial insulin improved significantly in both groups (P < 0.05). The maximum insulin concentration occurred earlier in the repaglinide group than that in the gliclazide group. AUC(ins) increased in both groups (P < 0.05), but no significant difference was found between groups. ΔI(30)/ΔG(30) increased in both groups (P < 0.05), especially in the repaglinide group (P < 0.05). Triglyceride and total cholesterol decreased significantly in the repaglinide group in some time points, while no significant change was observed in the gliclazide group.
  
  
  CONCLUSIONS
  Repaglinide and gliclazide had similar effects on glycaemic control and total insulin secretion, while repaglinide had more effects on improvements in β-cell function and lipid metabolism.
authors.affiliation: Institute of Endocrinology and Metabolism, Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China. 13873137337@vip.sina.com
authors.forename: Hong
authors.initials: H
authors.lastname: Zhang
authors.forename: Ping
authors.initials: P
authors.lastname: Bu
authors.forename: Yan-Hong
authors.initials: YH
authors.lastname: Xie
authors.forename: Juan
authors.initials: J
authors.lastname: Luo
authors.forename: Min-Xiang
authors.initials: MX
authors.lastname: Lei
authors.forename: Zhao-Hui
authors.initials: ZH
authors.lastname: Mo
authors.forename: Er-Yuan
authors.initials: EY
authors.lastname: Liao
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000187:drug effects; D002219:Carbamates / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000378:metabolism; D005215:Fasting / Q000097:blood; D005260:Female; D005907:Gliclazide / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D019518:Postprandial Period / Q000187:drug effects; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D002219:Carbamates; D007004:Hypoglycemic Agents; D007328:Insulin; D010880:Piperidines; D014280:Triglycerides; C072379:repaglinide; D002784:Cholesterol; D005907:Gliclazide